Incheon, South Korea

Bon Joong Kim

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Bon Joong Kim: Innovator in Pharmaceutical Treatments

Introduction

Bon Joong Kim is a notable inventor based in Incheon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of hypertrophic cardiomyopathy. His innovative approach has the potential to improve patient outcomes and enhance the efficacy of existing treatments.

Latest Patents

Bon Joong Kim holds a patent for a pharmaceutical composition aimed at treating hypertrophic cardiomyopathy. The patent describes a composition that includes cibenzoline, specifically S(−)-cibenzoline or a pharmaceutically acceptable salt thereof, as the active ingredient. This invention offers a method for treating patients suffering from hypertrophic cardiomyopathy, demonstrating excellent efficacy and safety compared to conventional off-label standard of care. He has 1 patent to his name.

Career Highlights

Kim is associated with Celltrion Inc., a leading biopharmaceutical company. His work at Celltrion has allowed him to focus on developing innovative treatments that address critical health issues. His dedication to research and development has positioned him as a key player in the pharmaceutical industry.

Collaborations

Throughout his career, Bon Joong Kim has collaborated with talented professionals, including Hoon Namkoong and Bo Ram Lee. These collaborations have fostered a creative environment that encourages innovation and the development of groundbreaking treatments.

Conclusion

Bon Joong Kim's contributions to the field of pharmaceuticals, particularly in the treatment of hypertrophic cardiomyopathy, highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments that can significantly benefit patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…